Founded in 2000 and headquartered in Tübingen, Germany, CureVac N.V. (NASDAQ: CVAC) is a leading global clinical-stage biopharmaceutical company that specializes in research, development, and commercialization of transformative medicines based on messenger Ribonucleic Acid (mRNA). As one of the pioneers in the mRNA technology, CureVac's mission is to use its capabilities to advance mRNA science in order to address critical unmet medical needs and improve public health.
Having developed one of the largest libraries of naturally occurring mRNA sequences, CureVac's optimized mRNA is uniquely stable at room temperature, reducing the need for costly cold-chain logistics. Their innovative approach is used to produce a range of proactive therapies and vaccines, not limited to treatments for cancer and infectious diseases like COVID-19, among others.
CureVac’s first proprietary product candidate, under the umbrella of its COVID-19 vaccine program, CVnCoV, completed its Phase 2b/3 clinical trial and began the rolling submission process with the European Medicines Agency (EMA) in February 2021. Despite disappointing preliminary data, the company continues to progress on the development of its mRNA product candidates.
Further distinguished by its partnership approach, CureVac teams up with various organizations and companies such as the Bill & Melinda Gates Foundation, GSK, and others to harness the success of mRNA technology for a wider range of treatments.
In addition to its main headquarters in Germany, CureVac also has operational sites in Frankfurt and Boston, USA. Led by an executive team experienced in the biopharmaceutical industry, the publicly listed company has moved mRNA from bench to bedside and is committed to bringing new options to patients and physicians worldwide.
Underscoring its remarkable innovation in mRNA technology, CureVac N.V. was listed on the Nasdaq Global Market Exchange (NASDAQ: CVAC) on August 14, 2020, where it continues to showcase its ambition and progress in the life sciences sector. Despite the challenges encountered, the company remains at the forefront of mRNA technology, manifesting its expertise, resilience, and dedication to developing and delivering transformative medicines that can improve and save lives.